Restoring cancer's death sentence - PubMed (original) (raw)

Comment

Restoring cancer's death sentence

Anthony Letai. Cancer Cell. 2006 Nov.

Free article

Abstract

In this issue of Cancer Cell, two groups present data on the function of an antagonist of BCL-2, ABT-737. Both groups find that expression of MCL-1, an antiapoptotic protein related to BCL-2, is a key determinant of resistance to ABT-737. Lowering MCL-1 levels is an effective adjunct to BCL-2 antagonism, and both groups suggest ways that this might be accomplished practically in a clinical setting. The mechanism by which ABT-737 selectively kills cancer cells is discussed below in the context of these and prior reports of ABT-737's function. Antagonism of BCL-2 is an exciting anticancer strategy that may soon become a clinical reality.

PubMed Disclaimer

Comment on

• Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.
  Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, Andreeff M. Konopleva M, et al. Cancer Cell. 2006 Nov;10(5):375-88. doi: 10.1016/j.ccr.2006.10.006. Cancer Cell. 2006. PMID: 17097560
• The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
  van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DC. van Delft MF, et al. Cancer Cell. 2006 Nov;10(5):389-99. doi: 10.1016/j.ccr.2006.08.027. Cancer Cell. 2006. PMID: 17097561 Free PMC article.

Similar articles

• Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.
  Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, Andreeff M. Konopleva M, et al. Cancer Cell. 2006 Nov;10(5):375-88. doi: 10.1016/j.ccr.2006.10.006. Cancer Cell. 2006. PMID: 17097560
• Targeting multiple arms of the apoptotic regulatory machinery.
  Dai Y, Grant S. Dai Y, et al. Cancer Res. 2007 Apr 1;67(7):2908-11. doi: 10.1158/0008-5472.CAN-07-0082. Cancer Res. 2007. PMID: 17409392 Review.
• The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
  van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DC. van Delft MF, et al. Cancer Cell. 2006 Nov;10(5):389-99. doi: 10.1016/j.ccr.2006.08.027. Cancer Cell. 2006. PMID: 17097561 Free PMC article.
• ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
  Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Murotani Y, Matsumoto Y, Tanaka H, Strasser A, Taniwaki M, Maekawa T. Kuroda J, et al. Br J Haematol. 2008 Jan;140(2):181-90. doi: 10.1111/j.1365-2141.2007.06899.x. Epub 2007 Nov 20. Br J Haematol. 2008. PMID: 18028486
• Killing cancer cells by flipping the Bcl-2/Bax switch.
  Cory S, Adams JM. Cory S, et al. Cancer Cell. 2005 Jul;8(1):5-6. doi: 10.1016/j.ccr.2005.06.012. Cancer Cell. 2005. PMID: 16023593 Review.

Cited by

• Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
  Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, Bornmann W, Kantarjian H, Viallet J, Samudio I, Andreeff M. Konopleva M, et al. Cancer Res. 2008 May 1;68(9):3413-20. doi: 10.1158/0008-5472.CAN-07-1919. Cancer Res. 2008. PMID: 18451169 Free PMC article.
• Bcl-xL induces Drp1-dependent synapse formation in cultured hippocampal neurons.
  Li H, Chen Y, Jones AF, Sanger RH, Collis LP, Flannery R, McNay EC, Yu T, Schwarzenbacher R, Bossy B, Bossy-Wetzel E, Bennett MV, Pypaert M, Hickman JA, Smith PJ, Hardwick JM, Jonas EA. Li H, et al. Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2169-74. doi: 10.1073/pnas.0711647105. Epub 2008 Feb 4. Proc Natl Acad Sci U S A. 2008. PMID: 18250306 Free PMC article.
• Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma.
  VanBrocklin MW, Verhaegen M, Soengas MS, Holmen SL. VanBrocklin MW, et al. Cancer Res. 2009 Mar 1;69(5):1985-94. doi: 10.1158/0008-5472.CAN-08-3934. Epub 2009 Feb 24. Cancer Res. 2009. PMID: 19244105 Free PMC article.
• ABT-737 synergizes with Bortezomib to kill melanoma cells.
  Reuland SN, Goldstein NB, Partyka KA, Smith S, Luo Y, Fujita M, Gonzalez R, Lewis K, Norris DA, Shellman YG. Reuland SN, et al. Biol Open. 2012 Feb 15;1(2):92-100. doi: 10.1242/bio.2011035. Epub 2011 Nov 16. Biol Open. 2012. PMID: 23213401 Free PMC article.
• Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia.
  Lee S, Jeong J, Majewski T, Scherer SE, Kim MS, Tuziak T, Tang KS, Baggerly K, Grossman HB, Zhou JH, Shen L, Bondaruk J, Ahmed SS, Samanta S, Spiess P, Wu X, Filipek S, McConkey D, Bar-Eli M, Issa JP, Benedict WF, Czerniak B. Lee S, et al. Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13732-7. doi: 10.1073/pnas.0701771104. Epub 2007 Aug 16. Proc Natl Acad Sci U S A. 2007. PMID: 17702869 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database